Duke spinout Grid gets IP for CFH antibodies

Duke University (Durham, N.C.) granted Grid Therapeutics LLC (Durham, N.C.), formerly Cue Biologics LLC, exclusive rights to IP covering antibodies that target complement factor H (factor H; CFH) to treat cancer, and CFH-related diagnostics. Duke received a stake in Grid as part of the deal.

In early 2019, Grid plans to start Phase I testing of lead candidate GT103, a recombinant IgG3 mAb targeting CFH, to treat advanced solid tumors...